article thumbnail

Pharma responds to proposed EU pharmaceutical legislation reform

European Pharmaceutical Review

Pinsent Masons Charlotte Weekes, Senior Associate at Pinsent Masons shared with EPR : “The Commission’s ambitious pharma legislation review is the first significant review of the European system since 2004.” “It These amend and replace the existing general pharmaceutical legislation.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. Reducing market exclusivity. Conclusions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Bill could enhance UK clinical trial regulation

European Pharmaceutical Review

Benefits of The Future Clinical Trials Bill Chiefly, the Bill’s goal is to increase patient participation and overall, ensure clinical trials have the highest levels of safety while enabling greater regulatory pragmatism, the author explained. If achieved, this would boost the UK’s competitiveness as a leading international site for trials.

Ethics 83
article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Pharma 64
article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

Nonetheless, some stakeholders remain concerned with this new approach given the complexity of biological medicines and the need for patients to be treated individually and have called for further discussions with regulators and all stakeholders. The Impact of Biosimilar Competition in Europe, IQVIA, December 2021. Lausuntopalvelu.fi.

article thumbnail

A glance back to Pharma Integrates, London 2022 – part ii

pharmaphorum

It was a unique event, at which leaders from across the pharmaceutical pipeline addressed the needs of the industry, shared their own insights, and tackled debates on the crucial topics that influence the future of patient outcomes. When Milburn and Blair introduced competition in 2004-2008 it did start to make a difference.”

Pharma 76
article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

To achieve this objective, the regulation amends Directive 2011/24/EU on the application of patients’ rights in cross?border Article 15 proved that transparent and effective assessments of new technologies were crucial to ensure fair competition between stakeholders that operate in the EU. governmental healthcare organisations.